Medullary thyroid cancer treated by capecitabine

Anti-Cancer Drugs

Volumn 18, Issue 7, 2007, Pages 831-834

  Labidi, Sana Intidhar ^a,b   Gravis, Gwenaelle ^a   Tarpin, Carole ^a   Brun, Vincent ^b   Viens, Patrice ^a  

^a Department of Medical Oncology ^*  (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Capecitabine; Chemotherapy; Medullary thyroid carcinoma

Indexed keywords

CALCITONIN; CAPECITABINE; CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; TECHNETIUM 99M; THYROXINE; TUMOR MARKER;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; COMBINATION CHEMOTHERAPY; DIARRHEA; HAND FOOT SYNDROME; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 34250887457     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280adc8f3     Document Type: Article

References (28)

1. Girelli ME, Nacamulli D, Pelizzo MR, De Vido D, Milan C, Piccolo M, et al. Medullary thyroid carcinoma: clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. Thyroid 1998; 8:517-523.
2. Vitale G, Caraglia M, Cicarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001; 91:1797-1808.
3. Schlumberger M, Abdelmoumen N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid carcinoma with an alterning combination of 5FU-streptozacin and 5FU-dacarbazine. Br J Cancer 1995; 71:363-365.
4. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol 2004; 61:299-310.
5. Yang KP, Liang LF, Samman NA. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdrl gene and low proliferation fraction. Anticancer Res 1991; 11:1065-1068.
6. Droz JP, Rougier P, Goddefroy V, Schlumberger M, Gardet P, Parmentier C. Chemotherapy for medullary thyroid cancer. Phase II trials with adriamycin and cis-platinum administered as monochemotherapy. Bull Cancer 1984; 71:195-199.
7. Petursson SR. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 1988; 62:1899-1903.
8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J cancer 1998; 34:1274-1281.
9. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16:1795-1802.
10. McEvoy GK, editor. Capecitabine. In: AHFS drug information. Bethesda: American Society of Health-System Pharmacists; 2002: pp. 916-921.
11. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
12. Van Custom E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106.
13. 4-pentyloxycarbonyl- 5′-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 1998; 21:713-717.
14. Cao S, Lu K, Ishitsuka H, Rustum YM. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol 1997; 16:795.
15. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:2084-2091.
16. Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V, et al. Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 2003; 14:1378-1382.
17. Cartwright T, Lopez T, Vukelja SJ, Encarnacion C, Boehm KA, Asmar L. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 2005; 5:50-56.
18. Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, et al. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. Acta Oncol 2005; 44:230-235.
19. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27:23-44.
20. Minea LN, Stanculeanu DL, Cringeanu A, Anghel RM. Capecitabine monotherapy for elderly patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 23:797.
21. Ershler WB. Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data. Crit Rev Oncol Hematol 2006; 58:68-78.
22. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. Proc Am Soc Clin Oncol 2005; 23 (16S):4216.
23. Hoff PM, Hoff AO, Phan AT, Sherman SI, Yao J, White N, et al. Phase I/II trial of capecitabine (C), dacarbazine (D) and imatinib (I) (CDI) for patients (pts) metastatic medullary thyroid carcinomas (MTC). Proc Am Soc Clin Oncol 2006; 24 (18S):13048.
24. Droz J, Baudin E, Medvedev V, Delord J, Kane M, Kloos R, et al. Activity of irofulven (IROF) combined with capecitabine (CAPE) in patients (pts) with advanced thyroid carcinoma: phase II international multicenter study (preliminary results). Proc Am Soc Clin Oncol 2006; 24 (18S):15511.
25. Moley JF, Debenedetti MK, Dilley WG, Tisell LE, Wells SA. Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med 1998; 243:521-526.
26. Gimm O, Ukhat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 1998; 22:562-567.
27. Trump DL, Mendelsohn G, Baylin SB. Discordance between plasma calcitonin and tumor-cell mass in medullary thyroid carcinoma. N Engl J Med 1979; 301:253-255.
28. Lausson S, Volle GE, Bourges M, Pidoux E, Borrel C, Milhaud G, et al. Calcitonin secretion, C cell differentiation and proliferation during the spontaneous development of murine medullary thyroid carcinoma. Virchows Arch 1995; 426:611-617.